Literature DB >> 10101295

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

M Nakajima1, T Yokoi, M Mizutani, M Kinoshita, M Funayama, T Kamataki.   

Abstract

A genetic polymorphism was identified in the 5'-flanking region of human CYP1A2 gene, and its effect on the transcriptional activation of the CYP1A2 gene was investigated. Nucleotide sequence analysis revealed the existence of a point mutation from guanine (wild type) to adenine (mutated type) at position -2964 in the gene. This point mutation was detected by a polymerase chain reaction-restriction fragment length polymorphism method using DdeI or BslI restriction enzyme, and was proven to be genetically inherited. Allele frequency in 116 Japanese subjects showed 0.77 and 0.23 for the wild and mutated types of allele, respectively. The point mutation caused a significant decrease of CYP1A2 activity measured by the rate of caffeine 3-demethylation in Japanese smokers (p<0.05). Gel retardation analysis showed the existence of protein bound to the polymorphic locus. These results suggest that this polymorphism is a causal factor of decreased CYP1A2 inducibility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101295     DOI: 10.1093/oxfordjournals.jbchem.a022352

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  78 in total

1.  Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda.

Authors:  L Christiansen; A Bygum; A Jensen; K Thomsen; F Brandrup; M Hørder; N E Petersen
Journal:  Hum Genet       Date:  2000-12       Impact factor: 4.132

Review 2.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 3.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Development of analytical technology in pharmacogenetic research.

Authors:  Ann K Daly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-25       Impact factor: 3.000

5.  Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.

Authors:  Samar I Hamdy; Masahiro Hiratsuka; Kaori Narahara; Naomi Endo; Mervat El-Enany; Nadia Moursi; Mohammed S-E Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

6.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

7.  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.

Authors:  Sebastian Härtter; Anna Nordmark; Dirk-Matthias Rose; Leif Bertilsson; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

8.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Authors:  Natasa Djordjevic; Roza Ghotbi; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

Review 9.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

10.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.